Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Johns Hopkins, Baltimore, Maryland

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

START Dallas Fort Worth, Fort Worth, Texas